Physician profile
Joseph Patrick Mcgraw
NPI 1588624852
$2,886.64
in general payments reported to CMS, 2019-2025
19 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.73 · 2020: $144 · 2021: $442 · 2022: $568 · 2024: $390 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $728.23 | 2022-2025 | Envista Envy Iol, Stellaris, Miebo |
| Amgen INC. | $474.25 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $412.31 | 2019-2025 | Eysuvis, Rocklatan, Clareon |
| Sun Pharmaceutical Industries INC. | $345.37 | 2021-2024 | |
| Eyevance Pharmaceuticals LLC | $203.75 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $153.65 | 2021-2025 | Tecnis Simplicity |
| Rxsight INC | $125.00 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Tarsus Pharmaceuticals, INC. | $122.05 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $80.64 | 2022 | |
| Abbvie INC. | $44.08 | 2024-2025 | |
| Aerie Pharmaceuticals, INC. | $39.63 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.45 | 2021 | |
| Glaukos Corporation | $22.65 | 2020 | |
| Oyster Point Pharma, INC. | $22.46 | 2022 | |
| Beaver-Visitec International, INC. | $21.63 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.54 | 2021 | |
| Ivantis, INC | $18.90 | 2021 | |
| Allergan, INC. | $14.67 | 2021 | |
| Ocular Therapeutix, INC. | $14.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mcgraw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.